Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)

Plero Ruggenenti, Ilian Iliev, Grazia Maria Costa, Aneliya Parvanova, Annalisa Perna, Giovanni Antonio Giuliano, Nicola Motterlini, Bogdan Ene-Iordache, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE - In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS - This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS - Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24-48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18-0.65], P = 0.0012 unadjusted, and 0.35 [0.18-0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS - ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure-lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population.

Original languageEnglish
Pages (from-to)1629-1634
Number of pages6
JournalDiabetes Care
Volume31
Issue number8
DOIs
Publication statusPublished - Aug 2008

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)'. Together they form a unique fingerprint.

Cite this